Status:
COMPLETED
Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient
Lead Sponsor:
Reproductive & Genetic Hospital of CITIC-Xiangya
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Infertility
Eligibility:
FEMALE
40-45 years
Phase:
NA
Brief Summary
The purpose of study is to assess the efficacy of add-on estrogen pretreatment in GnRH antagonist protocol on oocyte retrieval as compared with GnRH antagonist protocol for patients with poor ovarian ...
Detailed Description
Women of advanced maternal age seeking ART treatment are characterized as poor ovarian responders in the process of ovarian simulation. Poor response to ovarian stimulation causes high cycle cancellat...
Eligibility Criteria
Inclusion
- Bologna criteria
- At least two of the following three features must be present:
- Advanced maternal age (≥40 years) or any other risk factor for POR
- A previous POR (≤3 oocytes with a conventional stimulation protocol)
- An abnormal ovarian reserve test (i.e. antral follicle count \< 5-7 follicles or AMH\< 0.5 - 1.1 ng/mL)
Exclusion
- Age ≥45 years,
- Patients who conducted PGD/PGS, and donor egg cycles were excluded.
- Presence of unilateral ovary absence
- Abnormal uterine deformity or structure.
- Spontaneous abortion patients with three or more (including biochemical pregnancy abortion)
- With other endocrine disease, ovulation disorders such as adrenal cortex function or thyroid dysfunction
- Have assisted reproductive technology contraindications or pregnancy contraindication of patients
Key Trial Info
Start Date :
November 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 18 2021
Estimated Enrollment :
552 Patients enrolled
Trial Details
Trial ID
NCT03300518
Start Date
November 15 2017
End Date
August 18 2021
Last Update
January 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Reproductive & Genetic Hospital of Citic-Xiangya
Changsha, Hunan, China